XORTX Therapeutics Inc. Reports Increased R&D Expenses and Wider Net Loss for H1 2025; EPS Falls to $(0.38) from $(1.07)

XORTX Therapeutics Inc. released its financial results for the three and six months ending June 30, 2025. The company reported a significant increase in research and development expenses, which rose to $186,751 for the three months ended June 30, 2025, compared to $67,683 in the same period in 2024. For the six-month period, research and development expenses increased to $463,060, up from $141,326 in 2024. The basic and diluted loss per common share for the three months ended June 30, 2025, was reported at $0.19, a change from a gain of $0.06 per share in the same period in 2024. For the six-month period, the basic and diluted loss per common share was $0.38, compared to a loss of $1.07 in the same period in 2024. The company continues to focus on its research and development initiatives, and no specific outlook or guidance was provided in the report. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-005439), on August 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here